Biolight Life Sciences Ltd. · TASE:BOLT
Biolight Life Sciences — Investor Presentation (May 2021)
13 slides from Biolight Life Sciences's investor presentation, May 5, 2021
Slide 1: Corporate Presentation
Corporate Presentation May 5, 2021 NON-BINDING TRANSLATION – The following presentation is a free translation of Company’s presentation in Hebrew published on the TASE. In the event of inconsistency between this version and the Hebrew one, the Hebrew language version shall prevail.
Slide 2: Forward Looking Statement
Forward Looking Statement • This presentation was prepared by BioLight Life Sciences Ltd. (“BioLight”) and contains only concise information. It does not include a detailed and/or complete information regarding BioLight, its subsidiaries and affiliates (together the "Company"), its activities or for
Slide 3: Prevalence of eye diseases is constantly increasing
Prevalence of eye diseases is constantly increasing 340M Dry eye syndrome 146M Diabetic retinopathy 76M Glaucoma These statistics are a small representation of a variety of diseases from which billions suffer 3
Slide 4: Today's Challenges and Unmet Needs / Tomorrow's Solutions
Today’s Challenges and Unmet Needs • Aging population • Prevalence of eye disease rising • Insufficient eye doctors in relation to population growth • Fear of losing eye sight (blindness) Tomorrow’s Solutions • Early detection 75% of global vision impairment • Better and personalized drugs • Improve
Slide 5: Holding Chart
Holding Chart BioLight Life Sciences Ltd. Subsidiaries 41% 90% 97% 82% affiliates * The final stage of the acquisition of IOPtima is expected to 4% 4.5% 5% 5% occur in the second quarter of 2021 5
Slide 6: Activities in Ophthalmology (Subsidiaries)
BioLight’s Activities in Ophthalmology (Subsidiaries) Develops the TeaRxTM technology, Develops advance designed to diagnose front of the Develops a sub- conjunctiva procedure using a laser eye diseases, by examining and implant (EYE-D) for the slow device for less invasive analyzing the composition
Slide 7: Activities in Ophthalmology (Subsidiaries-cont.)
BioLight’s Activities in Ophthalmology (Subsidiaries-cont.) Develops droplet formulas Develops drugs to treat eye for the delivery of oily diseases through an innovative molecules to the front of technology platform that the eye, for a variety of improves the delivery of eye drops diseases based on
Slide 8: Investments in Ophthalmology (affiliates)
BioLight’s Investments in Ophthalmology (affiliates) Develops an innovative Develops an innovative product, surgical procedure for the the TRS01, based on the Develops clinic laser device to enable treatment of the Glaucoma technological platform for the glaucoma patients to receive short & treatmen
Slide 9: Investments in Ophthalmology (affiliates)
BioLight’s Investments in Ophthalmology (affiliates) The next thing… Develops artificial intelligence (AI) solutions for a variety of retinal diseases 5% Status The Company seeks to expand its Is in the advanced stage of a portfolio of technologies and clinical trial in the U.S., in order products i
Slide 10: BioLight's assets & investments summary as of December 31, 2020 (K NIS)
BioLight’s assets & investments summary as of December 31, 2020 (K NIS) The data in the table below are Non-GAAP Cash 31,149 As of December 31, 2020 (1) Cash receivable 18,326 Expected proceeds from the fourth closing of IOPtima sale, expected to be on the second quarter of 2021, translated to NIS u
Slide 11: Highly Experienced Managing Team
Highly Experienced Managing Team Israel Makov, Chairman of the Board Yaacov Michlin, CEO Yifftach Biel, CFO Karin Gurevitz, Vice President Serves as the Chairman of the Board Sun Serves as the Co-Chairman (Life Served as BioLight corporate General Counsel& Company Secretary Pharmaceuticals, Chairman
Slide 12: Main Shareholders [TASE: BOLT]
Main Shareholders [TASE: BOLT] Israel Makov Public 14.39% Dilip Shanghvi 33.50% 14.22% Dan Oren 9.52% Rock One 19.05% 12
Slide 13: Email and company web site
Email: Biolight@bio-light.co.il Company web site: https://bio-light.co.il/
BioLight Life Sciences — Investor Presentation (May 2021) on 6ix